Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Cash & Equivalents (2016 - 2025)

Ascendis Pharma A's Cash & Equivalents history spans 8 years, with the latest figure at $421.9 million for Q4 2023.

  • For Q4 2023, Cash & Equivalents fell 7.01% year-over-year to $421.9 million; the TTM value through Dec 2023 reached $421.9 million, down 7.01%, while the annual FY2023 figure was $424.2 million, 9.5% down from the prior year.
  • Cash & Equivalents for Q4 2023 was $421.9 million at Ascendis Pharma A, down from $453.8 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $696.9 million in Q4 2020 and bottomed at $421.9 million in Q4 2023.
  • The 5-year median for Cash & Equivalents is $510.5 million (2021), against an average of $549.0 million.
  • The largest annual shift saw Cash & Equivalents surged 108.74% in 2019 before it dropped 26.75% in 2021.
  • A 5-year view of Cash & Equivalents shows it stood at $662.0 million in 2019, then rose by 5.27% to $696.9 million in 2020, then decreased by 26.75% to $510.5 million in 2021, then dropped by 11.12% to $453.8 million in 2022, then dropped by 7.01% to $421.9 million in 2023.
  • Per Business Quant, the three most recent readings for ASND's Cash & Equivalents are $421.9 million (Q4 2023), $453.8 million (Q4 2022), and $510.5 million (Q4 2021).